Ashling Wahner

In an MAIC, mogamulizumab led to an OS improvement vs vorinostat in patients with relapsed/refractory mycosis fungoides or Sézary syndrome.

Topical tofacitinib is tolerable and has shown preliminary efficacy in patients with early-stage mycosis fungoides.

Izalontamab brengitecan was approved in China for recurrent/metastatic NPC following disease progression on chemotherapy and PD-1/PD-L1 inhibition.

Priya Rastogi, MD, discusses findings from a sub-study of the GeparDouze trial evaluating the effects of ctDNA positivity on treatment outcomes in TNBC.

The European Commission approved first-line sacituzumab govitecan as monotherapy for unresectable/metastatic TNBC not eligible for PD-(L)1 inhibition.

Patients with metastatic breast cancer achieving a CR/deep PR with frontline T-DXd/pertuzumab had the most durable PFS outcomes in DESTINY-Breast09.

Starting TTFields with chemoradiotherapy did not significantly improve OS vs using TTFields in the maintenance phase in newly diagnosed glioblastoma.

Phase 1 data show that BGB-16673 is eliminated through intestinal and biliary excretion, limiting CYP3A-mediated interactions.

A retrospective analysis of 3234 patients with CLL/SLL showed that over half of those 75 to 79 years of age went on to receive second-line therapy.

Experts unpack key melanoma data shared during the 2026 ASCO Annual Meeting.

Tacabrutideg's safety profile was tolerable, and the drug had antitumor activity in BTK inhibitor–naive patients with CLL/SLL and other B-cell malignancies.

Treatment with subcutaneous blinatumomab generated high CR rates across 2 dosing regimens in pretreated, relapsed/refractory, Ph-positive B-ALL.

ASCO 2026 highlights show dostarlimab may deliver curative potential in dMMR endometrial cancer, while novel ADCs and fasting reshape ovarian care.

Gilteritinib generated comparable OS outcomes vs midostaurin in newly diagnosed FLT3-mutated AML, failing to meet the phase 3 trial primary end point.

The FDA approved capivasertib plus abiraterone and prednisone for PTEN-deficient metastatic androgen pathway modulation–naive or sensitive prostate cancer.

Revumenib yielded responses across subgroups with relapsed/refractory, NPM1-mutated AML and co-mutations, as well as in KMT2A-rearranged acute leukemia.

Azacitidine plus venetoclax and ivosidenib produced robust responses and induced high rates of MRD negativity in IDH1-mutated newly diagnosed AML.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in May 2026.

Experts highlight the most interesting and potentially paradigm-shifting head and neck cancer data to come out of the 2026 ASCO Annual Meeting.

Megan Kruse, MD, discusses CDK4/6 inhibitor decision-making for patients with HR-positive breast cancer and future directions for oral SERD and ADC use.

Read a refresh of the top FDA news in breast cancer from May 2026, including several key approvals across ER-positive and triple-negative disease.

The EU has approved the use of subcutaneous isatuximab delivered via OBI across all existing indications for IV isatuximab for multiple myeloma.

Breast cancer data from ASCO 2026 confirm the clinical benefits of several investigational treatment approaches across disease subtypes.

HER3-DXd is being evaluated in the ongoing phase 3 HERTHENA-Breast04 trial in locally advanced or metastatic HR-positive, HER2-negative breast cancer.

Post-surgery ctDNA status was prognostic for distant recurrence in early TNBC, and the prognostic value of ctDNA status per WGS outperformed pCR status.

At the 2026 ASCO Annual Meeting, 3.5-year follow-up findings from the phase 3 EV-302/KEYNOTE-A39 study have been presented.

David Dinh Tran, MD, PhD, discusses the use of LITT followed by pembrolizumab in patients with recurrent high-grade astrocytoma.

At the 2026 ASCO Annual Meeting, results from the 7-year update of the phase 3 CROWN study were presented.

Gabriel Zada, MD, discusses advanced surgical techniques for brain cancer in light of Brain Tumor Awareness Month.

The FDA extended the review period for camizestrant plus a CDK4/6 inhibitor in hormone receptor–positive breast cancer with an emergent ESR1 mutation.